Aqueduct Neurosciences Inc

Aqueduct Neurosciences Inc.:

At LSINW, Aqueduct Neurosciences discussed exciting new technology developments. This year, Aqueduct Neurosciences

presented their new medical device, SED; its purpose is to automatically control pressure and CSF flow in hospitalized

patients with drainage problems. Current devices do not allow the patient to have mobility, which means the patient needs

constant assistance. The new device developed by Aqueduct Neurosciences is a drain device controlled automatically,

allowing the patient to keep his/her mobility and be more autonomous. Consequently, patients will feel better during their

recovery, they will be safer (because the drainage is controlled automatically) and this patient autonomy will improve the

hospital's economics. Aqueduct Neurosciences is looking to partner with someone for the distribution of this SED device.

The technology was developed at the University of Washington, where the licensing is being issued. Their plan is to make

clinical trials post market. Aqueduct Neurosciences is seeking to raise $3 million to be able to afford operation costs

through 2014. Their next step is to test the device for its usefulness in the diagnosis of NPH (Normal Pressure

Hydrocephalus).